CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Bullish +75

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

📈 CASGEVY revenue reached $76 million in Q2 2026, marking a 78% quarter-over-quarter and 151% year-over-year increase.

✅ FDA approved CASGEVY for children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, expanding the addressable market.

🧬 Phase 1 clinical trials initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).

💰 Cash, cash equivalents, and marketable securities totaled $2.36 billion as of June 30, 2026.

📉 Net loss narrowed to $91.2 million in Q2 2026 from $208.5 million in the same quarter last year.

🔬 CTX310 (ANGPTL3) development continues in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia.

🤝 Collaboration with Vertex Pharmaceuticals leads global development and commercialization of CASGEVY on a 60/40 basis.

🧬 Zugo-cel (CTX112) advancing in Phase 1 trials for autoimmune diseases including lupus, sclerosis, and multiple sclerosis.

🩸 CTX611 (FXI inhibitor) advancing through Phase 2 trials for thromboembolic disorders with potential broad indications.

📈 Analysts maintained or upgraded ratings, with Citi raising its price target to $88 citing CASGEVY momentum.

Bullish Signals
  • CASGEVY revenue surged to $76 million in Q2 2026, driven by a 78% quarter-over-quarter and 151% year-over-year growth.
  • FDA approval for CASGEVY in children as young as two years old significantly expands the eligible patient population to approximately 5,500 individuals.
  • Strong cash position of $2.36 billion provides ample liquidity to fund pipeline development and commercialization efforts.
  • Net loss decreased substantially to $91.2 million from $208.5 million in the prior year quarter, indicating improving financial trajectory.
  • Initiation of Phase 1 trials for CTX340 and CTX460 demonstrates successful expansion into new therapeutic areas using proprietary SyNTase technology.
  • CTX310 program continues to advance with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress.
  • Strategic collaborations with Vertex and Sirius Therapeutics provide shared resources and global commercialization reach.
Risk Factors
  • Company reported a net loss of $91.2 million for the quarter, though this is an improvement over the previous year.
  • Ongoing efforts to secure sustainable reimbursement globally for CASGEVY remain underway in various markets.
  • Clinical trials for investigational candidates like CTX340 and CTX460 are still in early Phase 1 stages with long-term outcomes yet to be determined.
Full Analysis
CRISPR Therapeutics reported strong second-quarter 2026 financial results, driven by significant growth in its blockbuster gene-edited therapy CASGEVY. The company generated $76 million in revenue for the quarter, representing a 78% increase from the previous quarter and a 151% year-over-year surge. This momentum was bolstered by the FDA's recent approval of CASGEVY for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, expanding the eligible patient population to approximately 5,500 individuals. Beyond its commercial success, CRISPR Therapeutics advanced multiple in vivo and ex vivo pipeline programs. The company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency using its proprietary SyNTase editing platform. Additionally, development continues on CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress in August 2026. Financially, the company strengthened its balance sheet with $2.36 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, up from $1.98 billion a year prior. This increase was primarily fueled by $585 million in proceeds from convertible senior notes issued in March 2026. While the company reported a net loss of $91.2 million for the quarter, this represents a substantial improvement compared to the $208.5 million loss recorded in the same period last year, reflecting improved operational efficiency and revenue recognition. The press release also highlighted progress in its autoimmune and immuno-oncology portfolios, including the allogeneic CAR-T cell therapy zugo-cel and siRNA-based programs like CTX611 for thromboembolic diseases. Strategic collaborations with Vertex Pharmaceuticals and Sirius Therapeutics continue to support development and commercialization efforts globally, positioning CRISPR Therapeutics as a diversified leader in gene editing technologies.